Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Melanoma 1Carcinoma, Transitional Cell 1

Interventions

Specimen Handling 17Magnetic Resonance Spectroscopy 15Gemcitabine 13Cisplatin 8Biopsy 8Radiotherapy 7Mitomycin 6Cystoscopy 6pembrolizumab 5Trastuzumab 5Paclitaxel 5Fluorouracil 5cabozantinib 4atezolizumab 4Radiation 4erdafitinib 3dehydroftorafur 3Transurethral Resection of Bladder 3Sunitinib 3Sorafenib 3Platinum 3Nivolumab 3Mitozytrex 3Gene Expression Profiling 3Fluorodeoxyglucose F18 3Carboplatin 31,2-diaminocyclohexaneplatinum II citrate 3valrubicin 2tipifarnib 2sapanisertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Urinary Bladder Neoplasms × Interleukin-7 × Clear all
NCT03513952 2024-07-26

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 14 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡